Remnant lipoproteins induce endothelial plasminogen activator inhibitor-1

Biochemical and Biophysical Research Communications

Volumn 285, Issue 1, 2001, Pages 15-19

  Sawka, Anna M ^a   Singh, Ravinder J ^a   Hiddinga, H Jay ^a   McConnell, Joseph P ^a   Eberhardt, Norman L ^a   Caplice, Noel M ^a   O'Brien, Timothy ^a  

^a MAYO CLINIC   (United States)

Author keywords

Endothelial cells; Fibrinolysis; Plasminogen activator inhibitor 1; Remnant lipoproteins

Indexed keywords

ANTIGEN; LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

AORTA; ARTICLE; CARDIOVASCULAR DISEASE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; HUMAN CELL; HYPERLIPOPROTEINEMIA TYPE 3; INCUBATION TIME; MORBIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOSIS;

EID: 0034794740     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2001.5117     Document Type: Article

References (47)

1. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows
2. Apohpoprotein E: Cholesterol transport protein with expanding role in cell biology
3. Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia
4. Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism
5. Enrichment with apolipoprotein E characterizes post-prandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: A preliminary report
6. Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease
7. Apolipoprotein E isoform polymorphisms are not associated with insulin resistance: The Framingham Offspring Study
8. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease
9. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events
10. Uptake of cholesterol-rich remnant lipoproteins by human monocyte-derived macrophages is mediated by low density lipoprotein receptors
11. Membrane active lipids in remnant lipoproteins cause impairment of endothelium-dependent vasorelaxation
12. Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoprotein levels
13. Impaired endothelium-dependent acetylcholine-induced coronary artery relaxation in patients with high serum remnant lipoprotein particles
14. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries
15. Adenosine 5′-diphosphate as a factor in platelet aggregation induced by human plasma remnant lipoproteins
16. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors
17. Structure of human plasminogen activator inhibitor 1 gene: Nonrandom distribution of introns
18. The fibrinolytic system of the vascular wall
19. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
20. Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI1/vitronectin complexes
21. Plasminogen activator expression in human atherosclerotic vessels
22. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque
23. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease
24. Expression of the plasminogen activator system in the human vascular wall
25. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study
26. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
27. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
28. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm
29. Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age
30. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
31. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke
32. Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: Relation to stroke etiology
33. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients
34. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke
35. Progressive intermittent claudication is associated with impaired fibrinolysis
36. Changes in arterial expression of fibrinolytic system proteins in atherogenesis
37. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction: The PRIME Study
38. Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells
39. Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells
40. VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: Involvement of the VLDL receptor
41. Very-low-density-lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia
42. Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells
43. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo-A-1 immunoaffinity mixed gels
44. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation
45. Pathogenesis of type III hyperlipoproteinemia (dybetalipoproteinemia): Questions, quandries, and paradoxes
46. Apohpoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique monocyte-macrophage receptor
47. Protein kinase C-beta mediates lipoprotein induced generation of PAI-1 from vascular endothelial cells